WEST CHESTER, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in the development of technologies and solutions for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left atrial appendage, today announced fourth quarter and full year 2012 financial results.
Revenue for the fourth quarter of 2012 was $18.4 million, reflecting 9.5% growth (10.1% growth on a constant currency basis) over the fourth quarter of 2011. Revenue from U.S. product sales was $13.7 million, reflecting growth of 10.2%, and revenue from product sales to international customers was $4.7 million, reflecting growth of 7.8% (10.1% growth on a constant currency basis).
“We are pleased to report fourth quarter and full year 2012 results which provide a strong growth platform from which we can continue to build in 2013 and beyond. I continue to be impressed with the resiliency and talent of the team at AtriCure – we have a great brand and customer service ethic which permeate every aspect of the company,” said Mike Carrel, President and Chief Executive Officer of AtriCure.
Mr. Carrel continued, “AtriCure is emerging as the education leader in the field of atrial fibrillation, and I am confident in our ability to further develop and expand the market. With our recently completed financing in January, we have strengthened our balance sheet to successfully build and grow our business, and in 2013 expect to continue our investments in training and education, clinical science, international expansion and other commercial investments. We are transforming AtriCure into a commercially focused organization with a clear eye toward accelerating revenue growth, leveraging our operating structure and eventually driving profitability.”
2012 Financial Results
Revenue for 2012 was $70.2 million, an increase of $5.8 million or 9.1%, compared to 2011 revenue. Domestic revenue increased 7.5% to $52.6 million, driven by strong sales of ablation-related open-heart products and AtriClip products. International revenue was $17.6 million, an increase of $2.2 million or 14.0% (18.9% on a constant currency basis) when compared to $15.5 million for 2011. International revenue growth was driven primarily by an increase in product sales in direct European markets, Russia and Asia.
Gross profit for 2012 was $50.0 million compared to $47.0 million for 2011. Gross margin for 2012 was 71.2% compared to 73.0% for 2011. The decrease in gross margin was due primarily to an increased mix of revenue from international sales, slight pressure on prices, primarily in our clamp and clip products, an increase in capital equipment sales and our investment in manufacturing and quality systems to transition and maintain the manufacturing of PMA approved products and to support our expanding operations.
Operating expenses for 2012 increased 10.6%, or $5.5 million, to $57.2 million from $51.7 million for 2011. The increase in operating expenses was driven primarily by a combination of increased selling, marketing and training expenses as well as non-recurring severance and other charges during the year.
Loss from operations for 2012 was $7.2 million as compared to $4.7 million for 2011. Adjusted EBITDA, a non-GAAP measure, was a loss of $1.8 million for 2012 as compared to income of $0.1 million for 2011 (see reconciliation table below). Net loss per share was $0.47 for 2012 and $0.35 for 2011.
Cash, cash equivalents and investments were $12.0 million at December 31, 2012 and cash used in operations during 2012 was $1.9 million.
Fourth Quarter 2012 Financial Results
Revenue for the fourth quarter of 2012 was $18.4 million, an increase of $1.6 million or 9.5%, compared to fourth quarter 2011 revenue. Domestic revenue increased 10.2% to $13.7 million, driven by strong sales of ablation-related open-heart products and AtriClip products. International revenue was $4.7 million, an increase of $0.3 million or 7.8% (10.1% on a constant currency basis) when compared to $4.4 million for the fourth quarter of 2011. International revenue growth was driven primarily by an increase in sales in European markets.
Gross profit for the fourth quarter of 2012 was $13.0 million compared to $11.7 million for the fourth quarter of 2011. Gross margin for the fourth quarter of 2012 and 2011 was 70.8% and 70.0%, respectively. The increase in gross margin was due primarily to a decrease in manufacturing scrap partially offset by some pricing pressure in the clamp and AtriClip products.
Operating expenses for the fourth quarter of 2012 increased 10.6%, or $1.4 million, compared to the fourth quarter of 2011. The increase in operating expenses was driven primarily by an increase in selling, marketing and training expenses.
Loss from operations for the fourth quarter of 2012 was $1.9 million compared to $1.7 million for the fourth quarter of 2011. Net loss per share was $0.12 for the fourth quarter of 2012 and $0.13 for the fourth quarter of 2011.
Management projects that 2013 revenue will be in the range of $76.5 - $78.0 million, an increase of 9 - 11% from 2012.
Adjusted EBITDA, a non-GAAP measure, is projected to be a loss in the range of $3.0 to $5.0 million including the impact of the Medical Device Tax which is estimated to be in the range of $0.8 - $1.0 million for 2013. Management expects to continue making investments targeted at future revenue growth.
AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, February 28, 2013 to discuss its fourth quarter 2012 financial results. A live webcast of the conference call will be available online from the investor relations page of AtriCure’s corporate website at www.atricure.com.
You may also access this call through an operator by calling (888) 713-4217 for domestic callers and (617) 213-4869 for international callers at least 15 minutes prior to the call start time using reservation code 53242423.
The webcast will be available on AtriCure’s website and a telephonic replay of the call will also be available through April 7, 2013. The replay dial-in numbers are (888) 286-8010 for domestic callers and (617) 801-6888 for international callers. The reservation code is 18558054.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company providing innovative Atrial Fibrillation (Afib) solutions designed to produce superior outcomes that reduce the economic and social burden of Atrial Fibrillation. AtriCure’s Synergy Ablation System is the first and only device approved for the treatment of Persistent and Longstanding Persistent forms of Afib in patients undergoing certain open concomitant procedures. AtriCure’s AtriClip Left Atrial Appendage (LAA) exclusion device is the most widely implanted device for LAA management worldwide. The company believes cardiothoracic surgeons are adopting its ablation and LAA management devices for the treatment of Afib and reduction of Afib related complications such as stroke. Afib affects more than 5.5 million people worldwide.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that address activities, events or developments that AtriCure expects, believes or anticipates will or may occur in the future, such as earnings estimates (including projections and guidance), other predictions of financial performance, launches by AtriCure of new products and market acceptance of AtriCure’s products. Forward-looking statements are based on AtriCure’s experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond AtriCure’s control. These risks and uncertainties include the rate and degree of market acceptance of AtriCure’s products, AtriCure’s ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products, the timing of and ability to obtain reimbursement of procedures utilizing AtriCure’s products, competition from existing and new products and procedures or AtriCure’s ability to effectively react to other risks and uncertainties described from time to time in AtriCure’s SEC filings, such as fluctuation of quarterly financial results, reliance on third party manufacturers and suppliers, litigation or other proceedings, government regulation and stock price volatility. AtriCure does not guarantee any forward-looking statement, and actual results may differ materially from those projected. AtriCure undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
A further list and description of risks, uncertainties and other matters can be found in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.
Use of Non-GAAP Financial Measures
To supplement AtriCure’s condensed consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles, or GAAP, AtriCure uses certain non-GAAP financial measures in this release as supplemental financial metrics. Non-GAAP financial measures provide an indication of performance excluding certain items. Our management believes that in order to properly understand short-term and long-term financial trends, investors may wish to consider the impact of these excluded items in addition to GAAP measures. The excluded items vary in frequency and/or impact on our continuing operations and our management believes that the excluded items are typically not reflective of our ongoing core business operations. Further, management uses results of operations before these excluded items as a basis for its strategic planning. The non-GAAP financial measures used by AtriCure may not be the same or calculated the same as those used by other companies. Reconciliations of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in tables later in this release. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for AtriCure’s financial results prepared and reported in accordance with GAAP.
|CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS|
|(In Thousands, Except Per Share Amounts)|
|Three Months Ended December 31,||Twelve Months Ended December 31,|
|Cost of revenue||5,362||5,023||20,233||17,406|
|Research and development expenses||2,967||2,964||12,147||11,857|
|Selling, general and administrative expenses||11,887||10,471||45,065||39,870|
|Total operating expenses||14,854||13,435||57,212||51,727|
|Loss from operations||(1,852||)||(1,695||)||(7,198||)||(4,731||)|
|Loss before income tax expense||(1,990||)||(2,075||)||(7,484||)||(5,425||)|
|Income tax expense||(30||)||(5||)||(50||)||(31||)|
|Basic and diluted net loss per share||$||(0.12||)||$||(0.13||)||$||(0.47||)||$||(0.35||)|
Weighted average shares used in computing net loss per common share:
|Basic and diluted||16,332||15,861||16,190||15,672|
|CONDENSED CONSOLIDATED BALANCE SHEETS|
|December 31,||December 31,|
|Cash, cash equivalents and short-term investments||$||12,000||$||14,183|
|Other current assets||873||933|
|Total current assets||28,539||31,193|
|Property and equipment, net||3,430||2,351|
|Liabilities and Stockholders' Equity|
|Accounts payable and accrued liabilities||$||10,176||$||9,266|
|Current maturities of debt and capital lease obligations||2,029||1,543|
|Total current liabilities||12,205||10,809|
|Long-term debt and capital lease obligations||6,407||4,926|
|Additional paid-in capital||123,157||118,853|
|Other comprehensive income (loss)||77||(37||)|
|Total stockholders' equity||12,500||15,615|
|Total liabilities and stockholders' equity||$||32,431||$||33,859|
|CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS|
|Twelve Months Ended December 31,|
|Cash flows from operating activities:|
Adjustments to reconcile net loss to net cash used in operating activities:
|Depreciation and amortization||1,899||1,922|
Write-off of deferred financing costs and discount on long-term debt
Amortization of deferred financing costs and discount on long-term debt
|Loss (gain) on disposal of assets||40||(243||)|
|Amortization/accretion on investments||12||61|
|Change in allowance for doubtful accounts||1||28|
|Changes in assets and liabilities|
|Other current assets||57||(17||)|
|Accounts payable and accrued liabilities||(229||)||(188||)|
|Other non-current assets and liabilities||(198||)||(182||)|
|Net cash used in operating activities||(1,936||)||(1,986||)|
|Cash flows from investing activities:|
|Purchases of available-for-sale securities||(9,236||)||(12,649||)|
|Maturities of available-for-sale securities||9,400||16,506|
|Purchases of equipment||(2,985||)||(1,522||)|
|Net proceeds from the sale of assets||24||389|
|Net cash (used in) provided by investing activities||(2,797||)||2,724|
|Cash flows from financing activities:|
|Proceeds from borrowings of debt||10,000||7,500|
|Payments on debt and capital leases||(8,096||)||(4,046||)|
|Proceeds from stock option exercises||659||1,588|
|Payment of debt fees||(127||)||(81||)|
Proceeds from issuance of common stock under employee stock purchase plan
|Shares repurchased for payment of taxes on stock awards||(401||)||(783||)|
|Net cash provided by financing activities||2,662||4,847|
|Effect of exchange rate changes on cash and cash equivalents||65||(57||)|
|Net (decrease) increase in cash and cash equivalents||(2,006||)||5,528|
|Cash and cash equivalents - beginning of period||9,759||4,231|
|Cash and cash equivalents - end of period||$||7,753||$||9,759|
|RECONCILIATION OF GAAP RESULTS TO NON-GAAP RESULTS|
|Reconciliation of Non-GAAP Adjusted Earnings (Adjusted EBITDA)|
|Three Months Ended December 31,||Twelve Months Ended December 31,|
|Net loss, as reported||$||(2,020||)||$||(2,080||)||$||(7,534||)||$||(5,456||)|
|Income tax expense||30||5||50||31|
|Other expense (a)||138||380||286||694|
|Depreciation and amortization expense||379||430||1,899||1,922|
|Share-based compensation expense||527||690||3,468||2,939|
|Non-GAAP adjusted (loss) earnings (adjusted EBITDA)||$||(946||)||$||(575||)||$||(1,831||)||$||130|
|Three Months Ended December 31,||Twelve Months Ended December 31,|
|(a) Other includes:||2012||2011||2012||2011|
|Net interest expense||$||(182||)||$||(161||)||$||(791||)||$||(798||)|
|Grant income (expense)||30||(57||)||409||51|
(Loss) gain due to exchange rate fluctuation
|Non-employee stock option income (expense)||20||(38||)||179||23|